2015 Update on Parkinson disease

Cleveland Clinic Journal of Medicine

Volumn 82, Issue 9, 2015, Pages 563-568

  Fernandez, Hubert H ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE TRANSPORTER; LEVODOPA;

DIFFERENTIAL DIAGNOSIS; HUMAN; METABOLISM; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROCEDURES; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SYMPTOM ASSESSMENT;

ANTIPARKINSON AGENTS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; LEVODOPA; PARKINSON DISEASE; SYMPTOM ASSESSMENT; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84983168941     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.82gr.15004     Document Type: Article

References (17)

1. Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 68:434-440.
2. Hernán MA, Takkouche B, Caamaño-Isoma F, et al. A meta-analysis of coffee drinking, cigarette smoking, and risk of Parkinson's disease. Ann Neurol 2002; 52:276-84.
3. Ridgel A, Thota A, Vitek JL, Alberts JL. Forced, not voluntary, exercise improves motor function in Parkinson's disease patients. Neurorehabil Neural Repair 2009; 23:600-608.
4. Smith AD, Zigmond MJ. Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp Neurol 2003; 184:31-39.
5. Olanow CW, Rascol O, Hauser R, et al, for the ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361:1268-1278.
6. Pasternak B, Svanström H, Nielsen NM, Fugger L, Melbye M, Hviid A. Use of calcium channel blockers and Parkinson's disease. Am J Epidemiol 2012; 175:627-635.
7. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24:197-211.
8. Hauser RA, Ellenbogen AL, Metman LV, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 2011; 26:2246-2252.
9. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20:190-199.
10. Hung SW, Adeli GM, Arenovich T, Fox SH, Lang AE. Patient perception of dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2010; 81:1112-1115.
11. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342:1484-1491.
12. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000; 284:1931-1938.
13. Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 2013; 30:587-592.
14. Teva Neuroscience, Inc. Azilect prescribing information. www.azilect.com/Resources/pdf/AZI-40850-Azilect-Electronic-PI.pdf. Accessed June 29, 2015.
15. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23:82-85.
16. Adler CH, Ahlskog JE, eds. Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician. Totowa, NJ: Humana Press; 2000.
17. Machado A, Fernandez HH, Deogaonkar M. Deep brain stimulation: what can patients expect from it? Cleve Clin J Med 2012; 79:113-120.